UPSTAZA

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, UK.

Active ingredients

The drug UPSTAZA contains one active pharmaceutical ingredient (API):

1	Eladocagene exuparvovec UNII S51J6N56M7 - ELADOCAGENE EXUPARVOVEC
	Eladocagene exuparvovec is a gene therapy based on recombinant AAV2 vector containing the human cDNA for the DDC gene. After infusion into the putamen, the product results in the expression of the AADC enzyme and subsequent production of dopamine, and consequently, development of motor function in treated AADC-deficient patients.
	Read more about Eladocagene exuparvovec

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
UPSTAZA Solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
A16AB26		A Alimentary tract and metabolism → A16 Other alimentary tract and metabolism products → A16A Other alimentary tract and metabolism products → A16AB Enzymes
Discover more medicines within A16AB26

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3046722
FR	Base de données publique des médicaments	61876862
IT	Agenzia del Farmaco	050223015
LT	Valstybinė vaistų kontrolės tarnyba	1095124